1h Free Analyst Time
The Biperiden Market grew from USD 364.27 million in 2023 to USD 384.70 million in 2024. It is expected to continue growing at a CAGR of 5.69%, reaching USD 536.76 million by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
It operates by blocking acetylcholine receptors in the central and peripheral nervous system. This action helps in reducing the symptoms associated with Parkinson's disease, such as rigidity, tremors, and excessive salivation. Additionally, biperiden is employed to counteract the side effects of antipsychotic medications, including involuntary muscle movements. Its availability in various forms, including oral and injectable, allows for flexibility in administration based on patient needs. As with all medications, the use of biperiden must be closely managed under the guidance of a healthcare professional to balance therapeutic benefits against potential side effects. The increasing number of Parkinson's disease cases globally drives the demand for Biperiden. As older age groups are more prone to Parkinson's, the expanding elderly demographic fosters an Increasing need for biperiden. Moreover, Continuous research on improving Biperiden's efficacy and reducing side effects contributes to market growth. However, biperiden's anticholinergic side effects, such as dry mouth, blurred vision, and constipation, may limit its usability for some patients. Nevertheless, the development of biperiden formulations with improved delivery mechanisms, reduced side effects, and enhanced patient compliance presents significant opportunities. Expanding into emerging markets with increasing healthcare expenditure and untapped patient demographics offers considerable growth potential.
Regional Insights
The Biperiden market in the Americas is characterized by a robust healthcare infrastructure, high awareness of neurological disorders, and strong regulatory support. The United States, being the largest market in the region, demonstrates significant demand due to an aging population and the prevalence of Parkinson's disease and extrapyramidal symptoms. Regulatory approvals and insurance coverage policies significantly influence the market dynamics in this region. Furthermore, Latin America shows promising growth potential, attributed to improving healthcare facilities, rising healthcare expenditures, and increasing awareness of neurological disorders. In the EMEA region, Europe stands out as a central market for biperiden, supported by its advanced healthcare systems, high spending on healthcare, and an increasing incidence of Parkinson's disease. The presence of well-established pharmaceutical companies, coupled with favorable regulatory environments, further drives the market. The Asia Pacific region shows an opportunistic landscape for the growth of the biperiden market, driven by burgeoning populations, escalating healthcare needs, and increasing prevalence of Parkinson's disease and other related disorders. Countries including China and India are pivotal due to their immense population base and rapidly evolving healthcare sectors. Increased investments in healthcare infrastructure, growing middle-class populations, and rising awareness about neurological disorders are key factors propelling the market in this region.Market Insights
Market Dynamics
- The market dynamics represent an ever-changing landscape of the Biperiden Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
- Growing use of biperiden to treat parkinson’s disease globally
- Rising usage of biperiden in drug developement of drug-induced movement disorders
Market Restraints
- Limited awareness and high cost of biperiden manufacturing
Market Opportunities
- Ongoing research and development to enhance the applicability of biperiden-based drugs
- Emerging investments by pharmaceutical companies in biperiden production
Market Challenges
- Potential health affects associated with biperiden
Market Segmentation Analysis
- Administration: Increasing preferences for Oral administration owing to their ease of use and patient compliance
- Application: Proliferation of biperiden in drug-induced movement disorders as potent anticholinergic agent
Industry Insights
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biperiden Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biperiden Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Recent Developments
Merck Seals USD 610 Million Biobucks Deal to Acquire Preclinical Neurodegenerative Biotech Caraway
Merck & Co., a pharmaceutical company, announced a significant acquisition, underscoring its persistent efforts to diversify and strengthen its portfolio in the neurodegenerative disease sector. This acquisition signifies Merck's dedication to pioneering in the neurodegenerative disease domain. It marks a pivotal step in its quest to foster innovative therapeutic solutions, reinforcing its position in the biopharmaceutical industry.AbbVie Acquires Parkinson’s Drug in Latest Biotech Buyout
AbbVie announced the acquisition of a burgeoning biotech firm and its experimental therapy for Parkinson's disease. This move is part of AbbVie's series of strategic acquisitions to bolster its commitment to advancing treatment options in neurological disorders. By integrating this novel treatment into its extensive research and development pipeline, AbbVie reinforces its dedication to addressing patients' complex challenges with Parkinson's disease.Serina-AgeX Merger to Develop Treatment for Advanced Parkinson’s
Serina Therapeutics announced its strategic merger with a subsidiary of AgeX Therapeutics, a move to accelerate the development of SER-252 (POZ-apomorphine), the company's flagship treatment for advanced Parkinson's disease. Operating under the Serina banner post-merger, the company focuses on advancing this pioneering therapy into clinical trials. This collaborative effort highlights a significant step forward in offering a new therapeutic option for those grappling with the advanced stages of Parkinson's disease.Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biperiden Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.Key Company Profiles
The report delves into recent significant developments in the Biperiden Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., ACTYLIS, Adooq Bioscience LLC, BioCrick BioTech, Biotechne Corporation, Clearsynth, Enomark, MANUS AKTTEVA BIOPHARMA LLP, Merck KGaA, NIKSAN PHARMACEUTICAL, Rafa Laboratories Ltd., SAKHIYA PHARMA CHEM, Salvavidas Pharmaceutical Pvt. Ltd., Shreeji Pharma International, Simson Pharma, and Synnat Pharma.Market Segmentation & Coverage
This research report categorizes the Biperiden Market to forecast the revenues and analyze trends in each of the following sub-markets:Administration
- Injection
- Oral
Application
- Drug-induced Movement Disorders
- Parkinson Disease
- Touret Syndrome
Region
Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Purchase of this report includes 1 year online access with quarterly updates
Purchase of this report includes 1 year online access with quarterly updates
Table of Contents
1. Preface
2. Research Methodology
5. Market Insights
6. Biperiden Market, by Administration
7. Biperiden Market, by Application
8. Americas Biperiden Market
9. Asia-Pacific Biperiden Market
10. Europe, Middle East & Africa Biperiden Market
11. Competitive Landscape
12. Competitive Portfolio
List of Figures
List of Tables
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- ACTYLIS
- Adooq Bioscience LLC
- BioCrick BioTech
- Biotechne Corporation
- Clearsynth
- Enomark
- MANUS AKTTEVA BIOPHARMA LLP
- Merck KGaA
- NIKSAN PHARMACEUTICAL
- Rafa Laboratories Ltd.
- SAKHIYA PHARMA CHEM
- Salvavidas Pharmaceutical Pvt. Ltd.
- Shreeji Pharma International
- Simson Pharma
- Synnat Pharma
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 183 |
| Published | June 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 384.7 Million |
| Forecasted Market Value ( USD | $ 536.76 Million |
| Compound Annual Growth Rate | 5.6% |
| Regions Covered | Global |
